Advertisement

Topics

Companies Related to "Cerenis Therapeutics Novasep awarded million funding from French" [Most Relevant Company Matches] RSS

00:20 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "Cerenis Therapeutics Novasep awarded million funding from French" found in our extensive corporate database of over 50,000 company records.

Showing "Cerenis Therapeutics Novasep awarded million funding from French" Companies 1–25 of 4,200+

Extremely Relevant

Cerenis Therapeutics SA

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by Cerenis' team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are pos...


Relevant

Novasep

Groupe Novasep is a unique, technology-driven company serving the Life Sciences, specialty chemicals industries and other markets. The ambition of Novasep Corporate is to be a first-choice partner of the Life Science Industries, thanks to the assets and the structure of our group. Novasep Process expertise on purification engineering allows us to develop new separation processes and improve existi...

Normandie Développement Rouen

An Internationally Renowned French and European Region! 3.2 million inhabitants, 5th biggest French economic region, 2nd largest region for industrial investments per capita, Number one French port complex on the Channel seaboard, only 2 hours from Paris, 3 major employment areas: Rouen (725,000 inhab.), Le Havre (360,000 inhab.) and Caen-Bayeux (485,000 inhab.), World renowned tourist landmarks ...


Maverick Therapeutics Inc.

Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverick’s highly innovative platform is designed to deliver potent activity with increased tumor specificity and reduced toxicity, resulting in superior therapeutics for cancer patients and improved clinical success. Maverick was founded by M...

UCLA School of Nursing

The UCLA School of Nursing is redefining nursing through the pursuit of uncompromised excellence in research, education, practice, policy and patient advocacy. Rated among the nation’s top nursing schools by U.S. News & World Report, the school also is ranked No. 7 in nursing research funded by the National Institutes of Health and No. 1 in NIH ...

Bavarian Nordic

Bavarian Nordic initiated the development of IMVAMUNE® in 1999 and began the first clinical study in 2001. In 2003, Bavarian Nordic was awarded a contract, valued at $29 million, from the U.S. National Institutes of Health (NIH), for the further development of IMVAMUNE®. In 2004, Bavarian Nordic was awarded its second U.S. Government contract, valued at $115 million, to continue advanced devel...

Bayhill Therapeutics, Inc

Bayhill Therapeutics was incorporated in 2001 and raised its Series A funding 2002 and its Series B funding in early 2005. The company currently occupies approximately 23,000 square feet of laboratory and office space. Its state of the art research labs are focused on evaluating its therapeutic candidates in model systems of MS, IDDM and other autoimmune disorders, and in pre-clinical development ...

OSEO

OSEO group was born in 2005, by bringing together ANVAR (French innovation agency) and BDPME (SME development bank), around a mission of general interest supporting the regional and national policies. Its mission is to provide assistance and financial support to French SMEs and VSEs in the most decisive phases of their life cycle : start up, innovation, development, business transfer / buy out. By...

KPI Therapeutics, Inc.

KPI Therapeutics is a development and funding consortium aimed at moving a diversified portfolio of novel drug programs into the clinic so they can be partnered for new medicines. KPI’s objective is to become a self-sustaining company with a robust pipeline of therapeutics through revenue from portfolio investments.

Bioam Gestion - Fonds Bioam

With a subscribed capital of €51 million, Bioam, is a venture capital fund dedicated to early-stage financing of biotech companies. Bioam combines 3 specificities : Seed funding : very early-stage capital investment. Focus on Biotechnology and its applications in the healthcare, agrifood and environment industries. Founding investors include the three French National Research Institutes :CNR...

Development Specialists, Inc.

DSI’s outstanding service was awarded in the “Reorganization of the Year (Middle Market);” "Consumer and Retail Products (Over $50 Million) Sale of the Year;” and “Real Estate Deal of the Year (Under $500 Million)" categories.

TESARO, Inc.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. Earlier this year, TESARO secured $60 million in start-up funding from New Enterprise Associates (NEA) and the TESARO founders. TESARO ...

The Mesothelioma Applied Research Foundation

The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma re...

Osprey Pharmaceuticals U.S.A., Inc.

Osprey Pharmaceuticals U.S.A. is focused on the development of protein therapeutics for the treatment of inflammatory and autoimmune conditions based on the company's proprietary therapeutic platform of Leukocyte Population Modulators (LPMs). Osprey Pharmaceuticals U.S.A. is advancing a pipeline of proprietary LPMs, novel fusion protein therapeutics designed to selectively and systematically neutr...

The Medical Capital

The Medical Capital initiative is a collaboration of Cleveland’s internationally renowned clinical, educational, and research institutions, philanthropies, government, and economic development engines. Convened by BioEnterprise, the initiative promotes the vibrant biomedical and healthcare industry in the 18-county Northeast Ohio region. The Medica...

CureDuchenne Ventures LLC

CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has funded seven research projects that have advanced to human clinical trials. CureDuchenne has leveraged $100 mi...

Merchant Cash and Capital

Since 2005, Merchant Cash and Capital, LLC, has been one of the nation's business cash advance funding leaders. MCC has provided more than $600 million in financing to over 12,500 distinct customers and a total of over 27,000 advances. For more information about MCC and its innovative small business-focused funding programs, please visit us at www.merchantcashand...

BioMolecular Therapeutics

BMT elucidates modulation of host defense mechanisms responsible for inflammatory and autoimmune diseases. The major disease areas in which BMT is conducting research are atherosclerosis, rheumatoid arthritis and certain forms of allergies. With a staff of more than 50 researchers and initial € 12 million of corporate and public funding, BMT generates break-through innovations which can be turne...

Imalux Corporation

Imalux Corporation was founded in 1996, based on a novel imaging technology, Optical Coherence Tomography (OCT). In 2000, initial seed funding enabled Imalux to start the process of commercialization. Since that time, with additional funding totaling more than $10 million, Imalux succeeded in being the first OCT company to develop and bring to market a platform OCT imaging system

Angelman Syndrome Foundation

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginning in 2005. For more information on the Foundation, please visit www.angelman.org.

Antegrin Therapeutics, Inc.

Antegrin Therapeutics, Inc., is a pharmaceutical company dedicated to developing novel treatments for fibrotic diseases. The company aims to select its first clinical development candidate in 2016 and has received funding from BioGenerator, the Missouri Technology Corporation, the iSelect Fund, and other investors. For more information, please visit...

Apollo Therapeutics

The Apollo Therapeutics Fund is a unique collaboration between three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline and Johnson & Johnson) and the technology transfer offices (TTOs) responsible for commercialising the research from Imperial College London, UCL (University College London) and the University of Cambridge. The £40m fund will...

France Biotech

France Biotech is the French biotechnology association and the industry representative. Its mission is to contribute to position France and Europe as leaders in the Life sciences industry. France Biotech is acting on the four key factors of success for a strong biotechnology industry: • improving the academic R&D dynamics and funding: France Biotech supported the Strategic Council for Innovation...

Clorox

The Clorox Company is a leading manufacturer and marketer of consumer products with fiscal year 2009 revenues of $5.5 billion. Clorox markets some of consumers' most trusted and recognized brand names, including its namesake bleach and cleaning products; Green Works(®) natural cleaners; Armor All(®) and STP(®) auto-care products; Fresh Step(®) and Scoop Away(®) cat litter; Kingsford(®) charc...

Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately-held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. The Company’s most advanced drug candidate, AMRS00...


More From BioPortfolio on "Cerenis Therapeutics Novasep awarded million funding from French"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks